Clinician Attitudes, Training, and Beliefs About Cannabis: An Interprofessional Assessment

Cannabis Cannabinoid Res. 2023 Jun;8(3):547-556. doi: 10.1089/can.2021.0022. Epub 2021 Dec 31.

Abstract

Background: Medical use of cannabis is growing in popularity across the United States, but medical education and clinician comfort discussing cannabis use for medical purposes have not kept pace. Materials and Methods: A total of 344 clinicians in the state of Pennsylvania (response rate 14%) completed a brief online survey about their attitudes, training, and experiences regarding medical cannabis and certifying patients to use medical cannabis. Results: Only 51% of clinicians reported completing any formal training on medical cannabis. Compared with noncertifying clinicians (pharmacists, nurse practitioners, and physician assistants), physicians were significantly more comfortable with patient use of medical cannabis, saw fewer risks, more benefits, and felt better prepared to discuss its use with vulnerable populations. All clinicians noted significant limitations to their understanding of how medical cannabis can affect patients, and many indicated a desire for more research and training to fill in gaps in their knowledge. Conclusions: Insufficient medical curricula on the medical uses of cannabis are available to interprofessional clinicians across their disciplines, and clinicians report significant deficits in their knowledge base about its effects. Additionally, these data suggest an urgent need to expand training opportunities to the full spectrum of clinicians as all are involved in caring for patients who use medical cannabis.

Keywords: medical cannabis; medical education; workforce training.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cannabinoid Receptor Agonists
  • Cannabis*
  • Curriculum
  • Hallucinogens*
  • Humans
  • Medical Marijuana* / therapeutic use
  • Physicians*
  • Surveys and Questionnaires
  • United States

Substances

  • Medical Marijuana
  • Hallucinogens
  • Cannabinoid Receptor Agonists